EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020

Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020

GAITHERSBURG, Md., July 16, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 30, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2020, recent business developments, revenue guidance for the third quarter of 2020, and financial outlook for full year 2020.

This conference call can be accessed live by telephone or by webcast:

Live Teleconference Information:

Dial in number: (855) 766-6521

International dial in number: (262) 912-6157

Conference ID: 7380905



Live Webcast Information:

Visit for the live webcast feed.

A replay of the call can be accessed on Emergent’s website under “.”

About Emergent BioSolutions

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit . Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

Media Contact:

Miko B. Neri

Senior Director, Corporate Communications

240-631-3392

EN
16/07/2020

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Reports First Quarter 2025 Financial Results

Emergent BioSolutions Reports First Quarter 2025 Financial Results First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior yearFirst Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior yearFirst Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior yearReaffirmed FY 2025...

May 7, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Prepar...

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario WINNIPEG, Manitoba, May 01, 2025 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced a maximum three-year agreement with a value of approximately $65 million to supply the Ontario Ministry of Health with NARCAN® Nasal Spray for the Ontario Naloxone Program (ONP). Since 2018, Emergent has supported the Ontario Ministry of...

May 1, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Report First Quarter 2025 Financial Results o...

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025. Participants can access the conference call live via , and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive a confirmation email detailing how to j...

April 22, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces Stock Repurchase Program

Emergent BioSolutions Announces Stock Repurchase Program GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company’s common stock on or before March 27, 2026. “As Emergent continues the turnaround phase of our multi-year transformation plan, we expect our investment priorities to remain focused on driving long-term growth and profitability,” said Joe Papa, president and CEO of Emergent. “This announcement reflects our confidence in the company’s...

March 31, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the "Inducement Plan"). The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the “Equity Award”) as of M...

March 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch